Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A study from Oxford and Basel universities may point the way to maintaining our immune systems as we get older.

© Nethuz - Shutterstock

In a paper in the journal Nature Immunology, scientists explain how they uncovered the effects of a protein called Foxn1, which is a critical factor in the development of an effective immune system.

Humans, like all higher animals, use T cells as part of the immune system, to fight off infections and cancer. T cells are generated in an organ called the thymus, where they closely interact with thymic epithelial cells (TEC) as they mature. People without TEC cannot generate T cells, severely compromising the immune system and consequently increasing the risk for life threatening infections and cancer.

More than 20 years ago the transcription factor Foxn1 was identified as an essential molecule for the normal development of TEC. However, the genes directly controlled by Foxn1 – and thus responsible for the various TEC functions – have remained unidentified.

Read the full story here.


 

Similar stories

Study raises hope of pre-school type 1 diabetes screening programme

Researchers in Oxford have launched the first UK study in the general population to test for early markers of type 1 diabetes before children develop symptoms or need insulin.

Developmental dynamics of the neural crest–mesenchymal axis in creating the thymic microenvironment

A new paper from researchers at the Department of Paediatrics and the Nuffield Department of Clinical Neurosciences has shown that fibroblasts in the thymus, often considered simply as dull “structural” cells, are much more complex than previously thought.

Angelman syndrome: first patient to receive potential therapy in Oxford

Things that seemed impossible, only a few years ago, are happening today. The first patient in Europe and one of the first in the world was injected with a potential treatment, GTX-102, in a phase I/II clinical trial in Oxford.

New model for infant leukaemia announced

The breakthrough could lead to development of new treatments for infant Acute Lymphoblastic Leukaemia.

Why it's so hard to treat pain in infants

For decades physicians believed that premature babies didn’t experience pain. Here’s what doctors know now – and the innovative solutions being embraced by today's caregivers.

Oxford to work with Brazil to establish clinical research hub

The University of Oxford and Brazilian Ministry of Health have announced a joint initiative to set up a global health and clinical research unit in Brazil led by Professor Sue Ann Clemens CBE.